

AMENDMENTS TO THE SPECIFICATION

Please enter the following amendments to the specification.

1. At page 1, before line 4, insert the following:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation application of US Patent Application No. 10/439,851, filed May 15, 2003 which is a continuation of US Patent Application No. 09/646,468, filed on October 26, 2000, which is incorporated by reference herein.

2. Amend the paragraph beginning at page 8, line 11:

Figures 5A-5H and 6A and 6B show investigations into the properties of monoclonal antibody 2D1 in chick cochleovestibular ganglia (CVG) culture.

3. Amend the paragraph beginning at page 40, line 15:

The deposit of hybridomas 2F7, 2D1 and 5H6 in support of this application was made at the European Collection of Cell Cultures (ECACC), Centre for Applied Microbiology & Research, Salisbury, Wiltshire SP4 0JG, UK. This deposit was made under the Budapest Treaty by Rademacher Group Limited (RGL), The Windeyer Building, 46 Cleveland Street, London W1P 6DB, UK. The deposits have been accorded accession numbers [accession numbers] 98051201 (deposited May 12, 1998), 98031212 (deposited March 12, 1998) and 98030901 (deposited March 9, 1998). RGL give their unreserved and irrevocable consent to the materials being made available to the public in accordance with appropriate national laws governing the deposit of these materials, such as Rules 28 and 28a EPC. The expert solution under Rule 28(4) EPC is also hereby requested.

4. After page 46, insert the following on a new page:

ABSTRACT OF THE DISCLOSURE

The present invention relates to anti-IPG antibodies, and in particular to monoclonal antibodies produced by hybridoma cell lines 2F7, 2D1, 5H6, and the use of these and other similar antibodies in the treatment and diagnosis of pre-eclampsia or diabetes, especially type I diabetes. A method of producing anti-IPG antibodies by immunizing an animal with IPG unconjugated to an immunogenic carrier is also disclosed.